首页 阿斯利康(usAZN)-基本信息

阿斯利康(usAZN)-基本信息

日报更新时间:06-24 15:34

周报更新时间:06-25 22:35

行情信息

今开价:66.6

最高价:67.545

成交量:5864656.0

昨收价:65.93

最低价:66.54

最新价:67.02

行情图标
概要信息

中文名称:阿斯利康


英文名称:AstraZeneca PLC


行业:医疗


简介:阿斯利康(AZN)是全球领先制药公司,由前瑞典阿斯特拉公司和前英国捷利康公司于1999年合并而成


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 持股信息
  • 领导人信息

阿斯利康(AstraZeneca)是全球领先制药公司,在6大治疗领域为患者提供富于创新,卓有成效的医药产品,包括:消化疾病、心血管疾病、癌症、中枢神经系统疾病、麻醉和呼吸疾病等,其中许多产品居于世界领先地位。阿斯利康AstraZeneca制药公司总部位于英国伦敦,研发总部则位于瑞典的斯德哥尔摩省的南泰利耶,是富时100指数成分股,2014年8月1日以548亿市值成为伦敦证券交易所上市的第六大公司,是中国处方药市场最大的跨国制药公司。阿斯利康制药AstraZeneca(AZN)产品百科: 肿瘤类药物:诺雷德(戈舍瑞林醋酸)、康士得(比卡鲁胺)、Nolvadex(他莫昔芬柠檬酸盐)和瑞宁得(阿那曲唑) 消化类药物:洛赛克(奥美拉挫)——全球销量最大的药品 心血管类药物:倍他乐克(酒石酸美托洛尔)、波依定(非洛地平)、Ramace(Ramipril)和Atacand(双氢克尿噻)、捷赐瑞(赖诺普利)和天诺敏(阿替洛尔) 呼吸类药物:普米克(布地奈德)、博利康尼(硫酸特布他林)、雷诺考特(布地奈德)、安可来(扎鲁司特,是一种口服的白三烯受体拮抗剂(LTRA),用于哮喘的维持治疗)和吸入剂推进装置 中枢神经系统药物:佐米格(佐米曲普坦) 麻醉类药物:赛罗卡因(利多卡因)——全球销量最大的局部麻醉药、得普利麻(丙泊酚)——全球销量最大的注射式常规麻醉药 农业化学产品:克无踪、Fusilade、Touchdown和Surpass(除草剂)、Karate(杀虫剂)、Amistar(灭真菌剂)产品全图: 点击查看大图阿斯利康制药AstraZeneca(AZN)历史百科: 1913年,400名医生和药剂师在瑞典创立Astra AB,是为阿斯利康前身之一; 1993年,英国公司Imperial Chemical Industries (ICI)分拆其制药、农业化学品和特种产品业务,成立Zeneca Group plc,是为阿斯利康另一前身; 1999年4月6日,Astra AB 和 Zeneca Group plc 合并,成立 AstraZeneca plc; 2005年,AstraZeneca以1.2亿英镑收购英国生物技术公司KuDOS Pharmaceuticals,并与Astex达成抗癌协作协议; 2006年,阿斯利康以7.02亿英镑收购Cambridge Antibody Technology; 2007年2月,AstraZeneca以1.5亿美金收购 Arrow Therapeutics; 2007年,阿斯利康以152亿美金收购MedImmune,获得了婴儿流感疫苗和抗病毒治疗产品组合。AstraZeneca随后将其所有的生物制品操作整合到一个专门的生物制剂部门——MedImmune; 2010年,AstraZeneca 收购抗生素研发公司 Novexel Corp(2004年由赛诺菲(Sanofi-Aventis)剥离抗感染部门成立); 2011年,AstraZeneca 收购中国基因工程公司 Guangdong BeiKang Pharmaceutical Company; 2012年2月,AstraZeneca 与 Amgen 宣布了一项合作,旨在治疗炎性疾病; 2012年4月,阿斯利康以12.4亿美金收购生物技术公司 Ardea Biosciences; 2012年6月,AstraZeneca 和 Bristol-Myers Squibb 宣布了一个两步走协议,共同收购生物技术公司Amylin Pharmaceuticals。协议内容包括:Bristol-Myers Squibb以53亿美元的现金收购Amylin,承担17亿美元的债务,阿斯利康则向Bristol-Myers Squibb支付34亿美元的现金,Amylin则被注入AstraZeneca 和 Bristol-Myers Squibb现有的关于糖尿病合作的合资公司中; 2013年,阿斯利康公司组织架构重构,并计划于2016年将公司总部由伦敦搬到剑桥。重组后,公司将着重于3个领域:(1)呼吸道,炎症和自身免疫;(2) 心血管与代谢疾病;(3) 肿瘤; 2013年10月,AstraZeneca 宣布以4.4亿美金收购生物科技肿瘤公司Spirogen ; 2014年5月19日,阿斯利康公司拒绝辉瑞公司的每股55英镑,估值为694亿英镑(1170亿美元)的“最终报价”; 2014年7月,AstraZeneca公司与Almirall达成协议,以21亿美金收购其子公司Almirall Sofotec及其肺部治疗,包括COPD药物Eklira; 2014年8月,阿斯利康公司宣布与Mitsubishi Tanabe Pharma就糖尿病肾病进行为期三年的合作; 2014年9月,AstraZeneca与礼来集团合作开发和商业化其候选产品——BACE抑制剂——AZD3292,用于阿尔茨海默病的治疗,该交易可能为公司带来高达5亿美元; 2014年11月,阿斯利康公司的生物制品研发部门MedImmune同意以收购超过1.5亿美元Definiens; 2014年11月,AstraZeneca同意将其脂肪营养不良治疗业务以超过3.25亿美元出售给Aegerion Pharmaceuticals; 2015年2月,阿斯利康公司宣布以约6亿美金收购Actavis品牌呼吸药在美国和加拿大的权利; 2015年2月,AstraZeneca宣布与Orca Pharmaceuticals合作开发用于治疗一些自身免疫性疾病的视黄酸相关孤儿核受体γ抑制剂,可为Orca带来高达1.225亿美元; 2015年3月中旬,AstraZeneca公司宣布将与Daiichi Sankyo(TYO:4568、NASDAQ:DSNKY)共同商业化纳洛昔戈(naloxegol),价值高达8.25亿美元; 截至2015年4月底,阿斯利康公司宣布合作价值约18亿美元,包括与Celgene开发和商业化MEDI4736,用于非霍奇金淋巴瘤,骨髓增生异常综合征和多发性骨髓瘤;公司的Medimmune部门还与Juno Therapeutics开展了协同临床试验,研究了癌症的联合治疗; 2015年6月下旬,AstraZeneca公司宣布已经与Eolas Therapeutics就Eolas Orexin-1受体拮抗剂(EORA)戒烟和其他治疗方案达成合作协议; 2015年7月,阿斯利康公司宣布将以2.15亿美元的价格将其Entocort (Budesonide)的权利出售给Tillotts Pharma; 2015年7月,Genzyme宣布将以3亿美金从阿斯利康收购罕见癌症药物Caprelsa(vandetanib); 2015年8月,AstraZeneca公司宣布已以5.1亿美金收购Heptares Therapeutics候选药物HTL-1071的全球开发和商业化权益,该产品专注于阻断腺苷A2A受体; 2015年8月,公司的MedImmune子公司根据一项协议以超过7.275亿美元收购Inovio Pharmaceuticals的INO-3112免疫疗法的专有权; 2015年11月6日,AstraZeneca 以27亿美金收购 ZS Pharma; 2015年12月,阿斯利康宣布以40亿美金获得了Acerta 的45%控股权; 2016年8月24日,阿斯利康表示,已同意把部分抗生素业务出售给辉瑞制药有限公司,价格是15.75亿美元外加专利许可费。交易涉及三款已获批的抗生素以及两款仍处于临床试验的药物。未来辉瑞将有权在美国以外的大部分市场销售这些药物。阿斯利康出售的资产不包括其生物抗感染药物。阿斯利康制药AstraZeneca(AZN)收购历史简图:

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Winslow Capital Management, LLC 6252146 0.24% 6252146 -- 2019-03-31
Capital Research and Management Company 26000429 0.99% 4150106 18.99% 2019-07-31
Fidelity Management & Research Company 36589438 1.39% -9849439 -21.21% 2019-07-31
Jennison Associates LLC 43462141 1.66% -2334646 -5.10% 2019-03-31
Dodge & Cox 49414201 1.88% -102200 -0.21% 2019-03-31
Fidelity Management and Research Company 55719404 2.12% 771624 1.40% 2019-03-31
PRIMECAP Management Company 56343156 2.15% 195230 0.35% 2019-03-31
Wellington Management Company LLP 64018087 2.44% 971602 1.54% 2019-03-31
FMR Inc 56832723 2.17% 458752 0.81% 2019-03-31
Bank of America Corporation 19134816 0.73% -6162649 -24.36% 2019-03-31
Fisher Asset Management, LLC 15374597 0.59% 409357 2.74% 2019-03-31
Arrowstreet Capital Limited Partnership 12459368 0.47% 752118 6.42% 2019-03-31
Vanguard 7323945 0.28% 3484822 90.77% 2019-07-31
Morgan Stanley - Brokerage Accounts 7433887 0.28% 5204220 233.41% 2019-03-31
Capital World Investors 8475021 0.32% 2474997 41.25% 2019-03-31
PGIM Investments LLC 9750593 0.37% -154225 -1.56% 2019-07-31
Hartford Funds Management Company, LLC 10272421 0.39% -923952 -8.25% 2019-07-31
Harbor Capital Advisors Inc 10285849 0.39% -3987629 -27.94% 2019-07-31
T. Rowe Price Associates, Inc. 11221510 0.43% -2528992 -18.39% 2019-03-31
Capital Research & Mgmt Co - Division 3 11250911 0.43% 846 0.01% 2019-03-31
GQG Partners LLC 5155269 0.39% 2157252 71.96% 2019-03-31
Goldman Sachs Asset Management, L.P. 5245835 0.40% 2211011 72.85% 2019-03-31
Goldman Sachs Group Inc 5414757 0.41% 2139012 65.30% 2019-03-31
New York Life Investment Management LLC 5253411 0.20% -205574 -3.77% 2019-05-31
BlackRock Inc 5061169 0.19% -1400489 -21.67% 2018-12-31
Epoch Investment Partners Inc 6031952 0.23% -1507433 -19.99% 2018-12-31
Franklin Resources Inc 4546170 0.17% 988663 27.79% 2018-12-31
Putnam Investments LLC 4524886 0.18% 113734 2.58% 2018-12-31
Putnam Investment Management, LLC 4079130 0.16% -46310 -1.12% 2019-01-31
Merrill Lynch & Co Inc 10946250 0.43% -2548632 -18.89% 2018-06-30
Managed Account Advisors LLC 18195468 0.72% -7035719 -27.89% 2018-06-30
Putnam Investment Management,LLC 8768534 0.35% 4373972 99.53% 2018-06-30
Federated Investment Management Company 4259513 0.17% -1075242 -20.16% 2018-03-31
Schafer Cullen Capital Management Inc 4234559 0.17% -228486 -5.12% 2018-06-30
Farallon Capital Management, L.L.C. 3850000 0.15% 285000 7.99% 2018-06-30
Wells Fargo Advisors, LLC 3748367 0.15% -107026 -2.78% 2018-06-30
Northern Trust Investments N A 3633487 0.14% 1245463 52.15% 2018-06-30
Astrazeneca Pharmaceuticals Savings and Security Plan 2643531 0.38% -- -- 2010-12-31
Raymond James & Associates 3550637 0.14% -326596 -8.42% 2018-06-30
Royal Bank Of Canada 2866728 0.11% -71941 -2.45% 2018-03-31
Goldman Sachs Asset Management LP 3879415 0.15% 1098817 39.52% 2018-03-31
Prudential Investments LLC 6069739 0.24% 541582 9.80% 2018-06-30
UBS Securities LLC 2901237 0.11% -265221 -8.38% 2017-12-31
Ameriprise Financial Services Inc 3108808 0.12% 127460 4.28% 2017-12-31
Holowesko Partners Ltd. 3221000 0.13% 179000 5.88% 2016-09-30
Viking Global Investors LP 4175587 0.17% 4175587 -- 2016-09-30
Cambiar Investors LLC 4508046 0.18% -2851743 -38.75% 2016-09-30
ClearBridge Advisors, LLC 5504319 0.22% 5241264 1992.46% 2016-09-30
Renaissance Technologies Corp 5702700 0.23% -263400 -4.41% 2016-09-30
BlackRock Advisors LLC 8079111 0.32% 872075 12.10% 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity 3008700 0.11% -1727000 -36.47% 2019-05-31
Dodge & Cox Stock Fund 32630573 1.24% -- -- 2019-06-30
Vanguard Wellington 28309970 1.08% -4922350 -14.81% 2019-03-31
Vanguard PrimeCap Fund 27776088 1.06% 34000 0.12% 2019-03-31
American Funds Washington Mutual Fund 15667900 0.60% 6154600 64.69% 2019-06-30
Harbor Capital Appreciation Fund 10285849 0.39% -3987629 -27.94% 2019-06-30
PrimeCap Odyssey Stock Fund 8468100 0.32% 170000 2.05% 2019-06-30
Vanguard PrimeCap Core Fund 6744200 0.26% 34000 0.51% 2019-03-31
American Funds American Mutual Fund 5991899 0.23% -- -- 2019-06-30
T. Rowe Price Health Sciences Fund 4762100 0.18% 610200 14.70% 2019-06-30
T. Rowe Price International Value Eq Fd 4234305 0.16% 356005 9.18% 2019-06-30
Fidelity Contrafund Commingled Pool 3193804 0.12% -- -- 2019-06-30
Putnam Equity Income Fund 3640393 0.14% -16207 -0.44% 2019-06-30
Vanguard Wellesley 3700467 0.14% 3700467 -- 2019-03-31
MainStay Large Cap Growth Fund 3925100 0.15% -38000 -0.96% 2019-06-30
Vanguard Equity Income Fund 4026017 0.15% 4026017 -- 2019-03-31
PrimeCap Odyssey Growth Fund 4088700 0.16% 558000 15.80% 2019-06-30
Dodge & Cox Balanced Fund 4112899 0.16% -38000 -0.92% 2019-06-30
Vanguard Wellesley Income Fund 3700467 0.14% 3700467 -- 2019-03-31
Prudential Series Fund Equity 3219766 0.12% -- -- 2019-03-31
Vanguard Morgan 3491497 0.13% 1904838 120.05% 2018-12-31
Hartford Dividend and Growth Fund 3152556 0.12% -- -- 2019-02-28
VA CollegeAmerica Amer Mutl Fd 5991899 0.24% 1464800 32.36% 2018-12-31
VA CollegeAmerica WA Mutl Inv Fd 7038300 0.28% 994773 16.46% 2018-12-31
VA CollegeAmerica Capital Inc Builder 2841600 0.11% -- -- 2018-12-31
American Funds Capital Income Bldr 2841600 0.11% -- -- 2018-12-31
PGIM Jennison Growth Fund 2575726 0.10% -28286 -1.09% 2018-12-31
VA CollegeAmerica WA Mutual 529B 5727327 0.23% -- -- 2018-06-30
Prudential Jennison Growth A 1623133 0.06% 523210 47.57% 2018-07-31
JNL/WMC Balanced B 1935702 0.08% 41979 2.22% 2018-06-30
American Funds NVIT Asset Allocation II 2001300 0.08% -- -- 2018-06-30
VA CollegeAmerica Cap Inc Bldr 529E 2841600 0.11% -- -- 2018-06-30
PRIMECAP Odyssey Growth 2913700 0.12% 155000 5.62% 2018-06-30
Dodge & Cox Stock 34646973 1.37% -1125000 -3.14% 2018-06-30
Vanguard PRIMECAP Inv 25362830 1.00% 892030 3.65% 2018-06-30
PRIMECAP Odyssey Stock 8045100 0.32% 170000 2.16% 2018-06-30
Harbor Capital Appreciation Instl 6815464 0.27% 6815464 -- 2018-06-30
Vanguard PRIMECAP Core Inv 6637200 0.26% 105000 1.61% 2018-06-30
Dodge & Cox Balanced 5070899 0.20% -495000 -8.89% 2018-06-30
VA CollegeAmerica Amercn Mutual 529E 4527099 0.18% -- -- 2018-06-30
T. Rowe Price International Gr & Inc 4390600 0.17% -1330300 -23.25% 2018-06-30
Hartford Dividend and Growth A 3763591 0.15% -- -- 2018-07-31
T. Rowe Price Health Sciences 4172500 0.16% 192100 4.83% 2018-06-30
Putnam Equity Income A 3692100 0.15% -- -- 2018-06-30
MainStay Epoch Global Equity Yield I 1630624 0.06% -71615 -4.21% 2018-05-31
Fidelity VIP Contrafund Inv 1698500 0.07% -47100 -2.70% 2018-04-30
Hartford Growth Opportunities A 1877058 0.07% 199653 11.90% 2018-01-31
Hartford Dividend and Growth HLS IA 1584533 0.06% -- -- 2018-01-31
T. Rowe Price International Stock 1534900 0.06% -36700 -2.34% 2017-12-31
Prudential Jennison Health Sciences A 1887238 0.07% 1069525 130.79% 2016-12-31
Vanguard Windsor 1988565 0.08% 235000 13.40% 2016-09-30
Vanguard Equity-Income Inv 3922662 0.16% 171564 4.57% 2016-09-30
Vanguard Wellesley Income 7629640 0.30% 192680 2.59% 2016-09-30
VA CollegeAmerica Washington Mutual 4133800 0.30% -- -- 2015-09-30
Prudential Jennison Health Sciences 3161570 0.20% -- -- 2015-08-31
Vanguard Windsor Fund 2974000 0.50% -- -- 2015-06-30
Fidelity® Ser Intrinsic Opportunities Fd 2200000 0.20% -300000 -12.00% 2015-07-31
MainStay Epoch Global Equity Yield Fund 2017180 0.20% -70600 -3.40% 2015-08-31
Hartford Dividend and Growth HLS Fund 1528236 0.10% -20850 -1.40% 2015-08-31
VA CollegeAmerica Cap Income Builder 8458000 0.70% 2141600 33.90% 2015-09-30
Hartford Equity Income Fund 1088940 0.10% -35530 -3.20% 2015-08-31
JHancock Global Shareholder Yield Fund 1016180 0.10% -57600 -5.40% 2015-08-31
Hartford Balanced Income Fund 1366840 0.10% -- -- 2015-08-31

Sherilyn S. McCoy Currently, Sherilyn S. McCoy occupies the position of Chairman for Certara USA, Inc. Ms. McCoy is also Member-President Business Leaders Cabinet at Rutgers State University of New Jersey and on the board of 8 other companies. She previously occupied the position of Vice Chairman-Executive Committee at Johnson & Johnson Global President-Baby & Wound Care Franchise at McNeil-PPC, Inc. and Chairman-Worldwide Franchise at Ethicon, Inc. (both are subsidiaries of Johnson & Johnson), Chief Executive Officer & Director at Avon Products, Inc. and Co-Chairman at US Foundation for Inspiration & Recognition of Science & Tech. Sherilyn S. McCoy received an undergraduate degree from the University of Massachusetts, a graduate degree from Princeton University and an MBA from Rutgers State University of New Jersey.
Pam P. Cheng Presently, Pam P. Cheng holds the position of Executive VP-Operations & Information Technology at AstraZeneca Plc. She is also on the board of Codexis, Inc. Ms. Cheng previously occupied the position of Senior VP-Global Supply Chain Management at Merck & Co., Inc. and President for MSD China Holding Co., Ltd. (a subsidiary of Merck & Co., Inc.). She received an MBA from Pace University and a graduate degree and an undergraduate degree from Stevens Institute of Technology.
Leif Valdemar Johansson Leif Valdemar Johansson is a Swedish businessperson who has been at the helm of 11 different companies. Currently, Mr. Johansson occupies the position of Non-Executive Chairman of AstraZeneca Plc. Mr. Johansson is also on the board of Autoliv, Inc., Boao Forum For Asia, Ecolean AB and F�0�1�0�9reningen Teknikf�0�1�0�9retagen i Sverige. In the past Mr. Johansson occupied the position of Chairman at Telefonaktiebolaget LM Ericsson and Chairman of Ericsson Danmark A (a subsidiary of Telefonaktiebolaget LM Ericsson), Chairman of European Automobile Manufacturers Association, Chairman at European Round Table of Industrialists, Chairman of Ericsson AB, Chief Executive Officer at Electrolux AB, President & Chief Executive Officer at Volvo AB, Chairman for Volvo Aero Corp., Chief Executive Officer at Volvo Flygmotor AB and Chairman for Royal Swedish Academy of Engineering Sciences. Mr. Johansson received a graduate degree from Chalmers University of Technology.
Philip Arthur John Broadley Philip Arthur John Broadley founded The European Insurance CFO Forum. He is Member-Code Committee at The Takeover Panel and on the board of 6 other companies. Mr. Broadley previously occupied the position of Chairman for The Hundred Group of Finance Directors, Chairman for The 100 Group, Trustee & Founding Member at The European Insurance CFO Forum, Director at Prudential Plc, Member-Insurance Working Group at International Accounting Standards Board, Treasurer for The London Public Library, Executive Director & Group Finance Director at Old Mutual Plc and Partner at Arthur Andersen (UK). He received an undergraduate degree from St. Edmund Hall Association and a graduate degree from London School of Economics & Political Science.
Rudolph Harold Peter Markham Rudolph Harold Peter Markham is on the board of United Parcel Service, Inc. and 4 other companies. In his past career he occupied the position of Non-Executive Director at Legal & General Group Plc, Non-Executive Chairman for Moorfields Eye Hospital NHS Foundation Trust, Chief Finance Officer & Executive Director at Unilever NV and Chairman & Chief Executive Officer of Unilever Japan KK (a subsidiary of Unilever NV) and Chief Financial Officer & Executive Vice President of Unilever Plc and Chairman at Unilever Australia Holdings Pty Ltd. (a subsidiary of Unilever Plc). Mr. Markham received a graduate degree from Christ's College.
Marcus Wallenberg Mr. Marcus Wallenberg is Vice Chairman at Investor AB, Chairman at Saab AB, Chairman at Saab Systems Pty Ltd., Chairman at Skandinaviska Enskilda Banken AB, Chariman at Patricia Industries, Inc. and Vice Chairman & Treasurer at The Institute of International Finance, Inc. He is on the Board of Directors at Investor AB, Temasek Holdings (Pte) Ltd., AstraZeneca Plc, Patricia Industries AB, Knut och Alice Wallenbergs Stiftelse and The Institute of International Finance, Inc. Prior to joining Patricia Industries, Mr. Wallenberg was employed as Chairman atLuossavaara-Kiirunavaara AB, a Managing Director at Investor AB (Investment Company), Chairman by Electrolux AB, Chairman by Skandinaviska Enskilda Banken AB, an Independent Director at Stora Enso Oyj, Deputy Chairman by LM Ericsson Telefon AB, Chairman by International Chamber of Commerce Sweden, and Vice Chairman by Telefonaktiebolaget LM Ericsson /Mobitex Wireless Data Div/. He also served on the board at Astra AB, Citibank NA, Cititrust Ltd. (Hong Kong), Deutsche Bank AG, EQT Holdings AB, S G Warburg Co. Ltd., SCANIA AB, Stockholm Holdings Ltd. and Stora Feldm�0�1�0�4hle. Mr. Wallenberg received his undergraduate degree from Royal Swedish Marine Academy.
Graham Andrew Chipchase Presently, Graham Andrew Chipchase holds the position of Chief Executive Officer & Director at Brambles Ltd. He is also on the board of AstraZeneca Plc. In the past Mr. Chipchase was Chief Executive Officer & Executive Director at Rexam Ltd., Finance Director at GKN Plc and Director-Planning & Financial Control at BOC Group, Inc. Mr. Chipchase received a graduate degree from Oriel College.
Marc Pierre Jean Dunoyer Marc Pierre Jean Dunoyer is Chief Financial Officer & Executive Director at AstraZeneca Plc and on the board of 5 other companies. In the past Mr. Dunoyer occupied the position of Global Head-Rare Diseases Unit at GlaxoSmithKline Plc and Chairman at GlaxoSmithKline KK (a subsidiary of GlaxoSmithKline Plc) and President-Asia Pacific at Hoechst Marion Roussel SA. Mr. Dunoyer received an MBA from Hautes Etudes Commerciales and a graduate degree from University Paris-Sorbonne (Paris IV).
Pam P. Cheng Presently, Pam P. Cheng holds the position of Executive VP-Operations & Information Technology at AstraZeneca Plc. She is also on the board of Codexis, Inc. Ms. Cheng previously occupied the position of Senior VP-Global Supply Chain Management at Merck & Co., Inc. and President for MSD China Holding Co., Ltd. (a subsidiary of Merck & Co., Inc.). She received an MBA from Pace University and a graduate degree and an undergraduate degree from Stevens Institute of Technology.
Leif Valdemar Johansson Leif Valdemar Johansson is a Swedish businessperson who has been at the helm of 11 different companies. Currently, Mr. Johansson occupies the position of Non-Executive Chairman of AstraZeneca Plc. Mr. Johansson is also on the board of Autoliv, Inc., Boao Forum For Asia, Ecolean AB and F�0�1�0�9reningen Teknikf�0�1�0�9retagen i Sverige. In the past Mr. Johansson occupied the position of Chairman at Telefonaktiebolaget LM Ericsson and Chairman of Ericsson Danmark A (a subsidiary of Telefonaktiebolaget LM Ericsson), Chairman of European Automobile Manufacturers Association, Chairman at European Round Table of Industrialists, Chairman of Ericsson AB, Chief Executive Officer at Electrolux AB, President & Chief Executive Officer at Volvo AB, Chairman for Volvo Aero Corp., Chief Executive Officer at Volvo Flygmotor AB and Chairman for Royal Swedish Academy of Engineering Sciences. Mr. Johansson received a graduate degree from Chalmers University of Technology.
Bahija Jallal Bahija Jallal is on the board of Anthem, Inc., The Johns Hopkins University, ADC Therapeutics SA and Viela Bio, Inc. and Chairman of Association for Women in Science and Executive Vice President at AstraZeneca Plc. In her past career she held the position of Vice President-Drug Assessment & Development at Chiron Corp. Dr. Jallal received a doctorate from Universit�0�1�0�8 Pierre et Marie Curie and a graduate degree from University Paris-Sorbonne (Paris IV).
Adrian Charles Noel Kemp Mr. Adrian C. Kemp is a Secretary at AstraZeneca Plc. He is on the Board of Directors at MedImmune Ltd., Medimmune UK Ltd., AstraZeneca US Investments Ltd., KuDOS Pharmaceuticals Ltd., Astrazeneca Intermediate Holdings Ltd. and Astrazeneca Treasury Ltd. He received his undergraduate degree from the University of Birmingham.
Genevi�0�1�0�8ve B. Berger Genevi�0�1�0�8ve B. Berger is Chief Research Officer at Firmenich SA. Dr. Berger is also on the board of AstraZeneca Plc and Air Liquide SA. Dr. Berger previously held the position of Chief Executive Officer of Centre National de la Recherche Scientifique, Chief Science Officer at Unilever NV, Chief Scientific Officer of Unilever Plc and Chief Research & Development Officer at Unilever France SA (a subsidiary of Unilever Plc), Professor at Assistance Publique des H�0�1�0�7pitaux de Paris SA, Professor at Groupe hospitalier Piti�0�1�0�8-Salp�0�1�0�9tri�0�1¨re, Technology Director at France Ministry of National Education, Higher Educ & Research, Head-Biosphysics & Nuclear Medicine at Religious Hospitallers of Saint Joseph of The Hotel Dieu of, Professor at Universit�0�1�0�8 Paris 1 and Professor at Universit�0�1�0�8 Pierre et Marie Curie. She received an undergraduate degree from �0�1‰cole normale sup�0�1�0�8rieure de Cachan, a doctorate from the University of Paris V, a doctorate from Universit�0�1�0�8 Pierre et Marie Curie and a doctorate from the University of Paris V.
Joseph G. Peter Presently, Joseph G. Peter occupies the position of Chairman at Nissan Motor Acceptance Corp. He is also on the board of AstraZeneca Plc, Renault Finance SA and Alliance Rostec Auto BV and Member of Cnbc Global Cfo Council. He previously held the position of CFO, Head-Investor Relations & Accounting at Nissan Motor Co., Ltd. and Vice President-International Finance Operations at General Motors Co. He received an undergraduate degree and an MBA from Wayne State University (Michigan).
Jos�0�1�0�8 Baselga Jos�0�1�0�8 Baselga founded Mosaic Biomedicals SL and Tango Therapeutics, Inc. He is on the board of Breast International Group and Foghorn Therapeutics, Inc. and Member of Institute of Medicine, Member of Association of American Physicians, Member of American Society of Clinical Investigation and EVP-Research & Development for Oncology at AstraZeneca Plc. In the past Dr. Baselga held the position of President of American Association for Cancer Research, Associate Director at Massachusetts General Hospital Cancer Center, Chairman-Hematology & Oncology Division at The General Hospital Corp., President of European Society for Medical Oncology, Chief Medical Officer for Memorial Sloan-Kettering Cancer Center, Director at American Society of Clinical Oncology, Professor at Weill Cornell Medical College, Professor at Harvard Medical School, Director-Medical Oncology & Hematology Division at Vall d'Hebron Institut d'Oncologia and Member of National Academy of Medicine of United States. Dr. Baselga received a doctorate from Autonomous University of Barcelona.
Jeffrey Pott Jeffrey Pott occupies the position of General Counsel for AstraZeneca Plc and Chairman for Aptium Oncology, Inc. (a subsidiary of AstraZeneca Plc). He previously was Principal at Drinker Biddle & Reath LLP. He received an undergraduate degree from Wheaton College (Illinois) and a graduate degree from Villanova University School of Law.
Pascal Soriot Presently, Pascal Soriot holds the position of Chief Executive Officer & Executive Director at AstraZeneca Plc and Chairman for AstraZeneca AB (a subsidiary of AstraZeneca Plc). Dr. Soriot is also on the board of Pharmaceutical Research & Manufacturers of America, Acerta Pharma BV and Viela Bio, Inc. In his past career he was Manager-District Sales at Roussel NZ Ltd., Director & Chief Executive Officer-Roche Group at Genentech, Inc., Chief Operating Officer of Roche Pharmaceuticals, Inc., Chief Operating Officer at Sanofi-Aventis U.S. LLC and Vice President-Asia Pacific at Hoechst Marion Rousel JP. He received an MBA from �0�1‰cole des Hautes �0�1‰tudes Commerciales de Paris and a doctorate from �0�1‰cole Nationale V�0�1�0�8t�0�1�0�8rinaire d'Alfort.
Colin Reisner Colin Reisner is Member of American Thoracic Society, Inc. and Head-Clinical Respiratory at AstraZeneca Plc. In the past Dr. Reisner was Senior Director-Respiratory Division at GlaxoSmithKline, Inc., Principal at Boehringer Ingelheim Corp., Executive Director-Global Respiratory Development at Novartis Corp., Assistant Consulting Professor at Duke University and Assistant Consulting Professor at Yale University. He received an undergraduate degree from the University of the Witwatersrand.
Jeffrey Pott Jeffrey Pott occupies the position of General Counsel for AstraZeneca Plc and Chairman for Aptium Oncology, Inc. (a subsidiary of AstraZeneca Plc). He previously was Principal at Drinker Biddle & Reath LLP. He received an undergraduate degree from Wheaton College (Illinois) and a graduate degree from Villanova University School of Law.
Shriti Vadera Ms. Baroness S. Vadera is Chairman at Santander UK Plc (Private Equity), Non-Executive Chairman at Santander UK Plc, Chairman at Santander UK Group Holdings Plc, Independent Non-Executive Director at BHP Billiton Plc, Independent Non-Executive Director at BHP Billiton Ltd., and Independent Non-Executive Director at AstraZeneca Plc. She is on the Board of Directors at BHP Billiton Plc, BHP Billiton Ltd., and AstraZeneca Plc. Ms. Vadera was previously employed as a Trustee by Oxfam Australia. She received her undergraduate degree from the University of Oxford.
Menelas N. Pangalos Menelas N. Pangalos is on the board of The Medical Research Council, Cambridge Judge Business School, Precision Medicine Catapult and Dizal Pharma and Member of Society For Neuroscience, Member of British Pharmacological Society and EVP-Research & Development Biopharmaceuticals at AstraZeneca Plc. Menelas N. Pangalos previously occupied the position of Chief Scientific Officer & Senior Vice President at Neuroscience Research Australia. Dr. Pangalos received an undergraduate degree from Imperial College London and a doctorate from the University of London.
Katarina Ageborg Katarina Ageborg occupies the position of Chief Compliance Officer & EVP-Sustainability at AstraZeneca Plc. In the past she held the position of President of AstraZeneca AB. She received a graduate degree from the University of Uppsala.
Thomas Kudsk Larsen Thomas Kudsk Larsen occupies the position of Investor Relations Contact at AstraZeneca Plc and Head-Investor Relations North America at Roche Holdings, Inc.
Deborah DiSanzo Deborah DiSanzo is on the board of AstraZeneca Plc and Project HOPE-The-People-To-People HealthFoundation, Inc. and General Manager-IBM Watson Health at International Business Machines Corp. Ms. DiSanzo previously held the position of Executive Vice President of Koninklijke Philips NV and Chief Executive Officer of Philips Healthcare (a subsidiary of Koninklijke Philips NV). She received an MBA from Babson College and an undergraduate degree from Merrimack College.
Pam P. Cheng Presently, Pam P. Cheng holds the position of Executive VP-Operations & Information Technology at AstraZeneca Plc. She is also on the board of Codexis, Inc. Ms. Cheng previously occupied the position of Senior VP-Global Supply Chain Management at Merck & Co., Inc. and President for MSD China Holding Co., Ltd. (a subsidiary of Merck & Co., Inc.). She received an MBA from Pace University and a graduate degree and an undergraduate degree from Stevens Institute of Technology.
Ruud Dobber Ruud Dobber is Executive VP-Biopharmaceuticals Business at AstraZeneca Plc. He previously was Chairman-Asia division at Pharmaceutical Research & Manufacturers of America. Dr. Dobber received a doctorate from the University of Leiden.
Leif Valdemar Johansson Leif Valdemar Johansson is a Swedish businessperson who has been at the helm of 11 different companies. Currently, Mr. Johansson occupies the position of Non-Executive Chairman of AstraZeneca Plc. Mr. Johansson is also on the board of Autoliv, Inc., Boao Forum For Asia, Ecolean AB and F�0�1�0�9reningen Teknikf�0�1�0�9retagen i Sverige. In the past Mr. Johansson occupied the position of Chairman at Telefonaktiebolaget LM Ericsson and Chairman of Ericsson Danmark A (a subsidiary of Telefonaktiebolaget LM Ericsson), Chairman of European Automobile Manufacturers Association, Chairman at European Round Table of Industrialists, Chairman of Ericsson AB, Chief Executive Officer at Electrolux AB, President & Chief Executive Officer at Volvo AB, Chairman for Volvo Aero Corp., Chief Executive Officer at Volvo Flygmotor AB and Chairman for Royal Swedish Academy of Engineering Sciences. Mr. Johansson received a graduate degree from Chalmers University of Technology.
Edward Bradley Edward Bradley is Senior VP & Head-Innovative Medicines Oncology at AstraZeneca Plc.
Fiona Cicconi Fiona Cicconi holds the position of Executive Vice President-Human Resources of AstraZeneca Plc.
Thomas Kudsk Larsen
Nazneen Rahman Founder of Tglclinical Genetic Testing Laboratory, Nazneen Rahman is on the board of AstraZeneca Plc. In her past career she held the position of Head-Genetics & Epidemiology Division at The Institute of Cancer Research: Royal Cancer Hospital, Head-Cancer Genetics at Royal Marsden NHS Foundation Trust and Director at Tglclinical Genetic Testing Laboratory. Dr. Rahman received a doctorate from the University of Oxford.
Sherilyn S. McCoy Currently, Sherilyn S. McCoy occupies the position of Chairman for Certara USA, Inc. Ms. McCoy is also Member-President Business Leaders Cabinet at Rutgers State University of New Jersey and on the board of 8 other companies. She previously occupied the position of Vice Chairman-Executive Committee at Johnson & Johnson Global President-Baby & Wound Care Franchise at McNeil-PPC, Inc. and Chairman-Worldwide Franchise at Ethicon, Inc. (both are subsidiaries of Johnson & Johnson), Chief Executive Officer & Director at Avon Products, Inc. and Co-Chairman at US Foundation for Inspiration & Recognition of Science & Tech. Sherilyn S. McCoy received an undergraduate degree from the University of Massachusetts, a graduate degree from Princeton University and an MBA from Rutgers State University of New Jersey.
David Fredrickson David Fredrickson is EVP & Global Head-Oncology Business Unit at AstraZeneca Plc. In his past career he occupied the position of President for AstraZeneca KK, Vice President-Specialty Care at AstraZeneca LP and Manager-Business Unit at Genentech, Inc. Mr. Fredrickson received an undergraduate degree from Georgetown University.
David Fredrickson David Fredrickson is EVP & Global Head-Oncology Business Unit at AstraZeneca Plc. In his past career he occupied the position of President for AstraZeneca KK, Vice President-Specialty Care at AstraZeneca LP and Manager-Business Unit at Genentech, Inc. Mr. Fredrickson received an undergraduate degree from Georgetown University.
David Fredrickson David Fredrickson is EVP & Global Head-Oncology Business Unit at AstraZeneca Plc. In his past career he occupied the position of President for AstraZeneca KK, Vice President-Specialty Care at AstraZeneca LP and Manager-Business Unit at Genentech, Inc. Mr. Fredrickson received an undergraduate degree from Georgetown University.
David Fredrickson David Fredrickson is EVP & Global Head-Oncology Business Unit at AstraZeneca Plc. In his past career he occupied the position of President for AstraZeneca KK, Vice President-Specialty Care at AstraZeneca LP and Manager-Business Unit at Genentech, Inc. Mr. Fredrickson received an undergraduate degree from Georgetown University.
Tony Mok Tony Mok is an entrepreneur who founded Chinese Thoracic Oncology Group, Sanomics Ltd. and Asia Thoracic Oncology Research Group. Presently, he is Chairman for Sanomics Ltd. and Secretary for Chinese Society of Clinical Oncology. Mr. Mok is also on the board of AstraZeneca Plc, Hutchison China MediTech Ltd. and American Society of Clinical Oncology and Treasurer of International Association for the Study of Lung Cancer. He previously was Chairman-Clinical Oncology Department at The Chinese University of Hong Kong. Mr. Mok received an undergraduate degree and a doctorate from the University of Alberta.

量化对比

全部评论 1050

  • 市场消息:欧盟人体用药委员会(CHMP)推荐批准阿斯利康乳腺癌药物Enhertu上市。

  • 【英国研究:混搭接种阿斯利康和辉瑞疫苗可增强对奥密克戎免疫力】据市场消息,在有关阿斯利康疫苗可对某些接种者造成副作用的报道发布后,英国和欧洲大部分地区决定将辉瑞疫苗作为某些年龄段人群的第二针疫苗,从而开创了一种自然的混搭接种实验。英国的最新数据表明,与接种过其他疫苗的人相比,这种特殊的混搭法对奥密克戎变种病毒形成了额外的免疫力。

  • 市场消息:阿斯利康寻求日本批准其新冠预防抗体组合Evusheld。

  • 【阿斯利康:Vaxzevria在欧盟获批为新冠疫苗第三剂加强针】阿斯利康表示,其新冠疫苗已在欧盟获批作为成年人的第三剂加强针。该公司表示,其Vaxzevria疫苗现在可以作为第三剂加强针,用于之前接种过Vaxzevria或其他欧盟批准的疫苗的患者。

  • 阿斯利康的新冠肺炎疫苗加强针(临床试验数据)获得CHMP(欧洲人用医药产品委员会)的积极评估。

  • 市场消息:阿斯利康广谱抗癌药Enhertu在美国被批准用于治疗HER2阳性乳腺癌。

  • 【阿斯利康美股盘前股价跌超1%】阿斯利康预警,今年来自新冠药物的总收入将录得低到中双位数百分比下降。

  • 阿斯利康2022年Q1 营收113.9亿美元,预期107.92亿美元。

  • 【日内请重点关注(以下均为北京时间)】 ① 全天 日本股市休市一天;② 13:30 法国一季度GDP初值;③ 14:45 法国4月CPI初值;④ 16:00 德国一季度GDP初值、瑞士央行行长乔丹在瑞士央行年度股东大会上发表讲话;⑤ 17:00 欧元区一季度GDP初值、4月调和CPI初值、3月M3货币供应;⑥ 18:30 俄罗斯央行公布利率决议;⑦ 美股盘前 埃克森美孚,雪佛龙,霍尼韦尔,艾伯维,阿斯利康,百时美施贵宝,发布业绩报告;⑧ 20:00 俄罗斯央行行长纳比乌琳娜召开货币政策新闻发布会;⑨ 20:30 美国3月核心PCE物价指数、个人消费支出(PCE)、个人收入,加拿大2月GDP;⑩ 22:00 美国4月密歇根大学消费者信心指数终值;⑪ 次日01:00 美国4月29日当周石油钻井数。

  • 【阿斯利康:努力实现新冠抗体疗法在海南博鳌先行先试】 “在今年,预期我们的新冠中和抗体在中国获批,不一定在乎它卖多少,相信一旦使用上,能够帮助到少数人群实现疫苗无法实现的免疫,对我们业务也有一定的帮助。”4月22日,博鳌论坛期间,阿斯利康全球执行副总裁、国际业务及中国总裁王磊在表示。阿斯利康方面表示,在努力将这款药物引入中国。阿斯利康将积极配合海南乐城医疗先行区管理局,协助其尽快实现替沙格韦单抗与西加韦单抗在海南博鳌的先行先试。(澎湃新闻)

  • 【艾德生物:与阿斯利康达成靶向药物临床研究合作】艾德生物公告,公司与阿斯利康签署了两份合作协议。分别为公司将与阿斯利康共同推进公司自主研发的伴随诊断产品用于在中国、欧盟和日本识别具有同源重组修复(HRR)基因突变的前列腺癌患者的伴随诊断注册;公司将与阿斯利康共同推进公司自主研发的另一款伴随诊断产品用于在欧洲地区识别具有BRCA突变的乳腺癌患者的伴随诊断注册。

  • 日本政府宣布取消4000万剂阿斯利康新冠疫苗合同,该数量占原先采购合同的三分之一。

  • 【港股午评:恒指跌1.31%失守22000点 开拓药业跌近14%】今日早盘,恒指低开,一度翻红,此后再度跳水,截止午盘,恒指跌1.31%,报21791.3点,药明生物跌超6%,领跌蓝筹。恒生科技指数跌2.12%,万国数据跌7.68%,快手跌近5%,百度、哔哩哔哩跌超4%,网易、腾讯等齐跌。医药股跌幅居前,开拓药业跌近14%,腾盛博药跌10%,康希诺生物跌近8%,心通医疗跌超7%。京东集团跌3.6%。京东集团宣布,京东集团总裁徐雷将接替刘强东,担任京东集团首席执行官。开拓药业股价昨日翻倍,今日股价高开低走,午盘大跌14%。和铂医药-B与阿斯利康签订HBM7022对外授权协议,公司股价涨23%,一度涨超50%。

  • 美股抗疫概念股上行,礼来涨幅达3%,阿斯利康、辉瑞涨超2%。

  • 【阿斯利康Evusheld长效抗体组合在欧盟获批】据悉,阿斯利康Evusheld(tixagevimab替沙格韦单抗与cilgavimab西加韦单抗组合)是一种长效抗体组合,已获准在欧盟上市,用于成年人和青少年(12岁及以上且体重40公斤及以上)广泛人群的新冠病毒暴露前预防。基于Evusheld临床开发项目获得的结果,欧盟委员会批准Evusheld在欧洲上市。Evusheld临床研究结果包括来自III期PROVENT暴露前预防试验的数据,该试验初步分析显示,与安慰剂相比,使用Evusheld的受试者发生有症状新冠感染的相对风险降低了77%;中位随访6个月分析显示,有症状新冠感染的相对风险降低了83%;保护作用至少持续6个月。Evusheld在临床试验中显示出良好的耐受性。 (21世纪经济报道)

  • 【阿斯利康Evusheld获欧盟批准】阿斯利康宣布Evusheld获欧盟批准用于12人及以上人群感染的COVID-19暴露前预防。

  • 【欧洲药管局推荐批准阿斯利康预防新冠药物上市】欧洲药品管理局24日推荐批准英国阿斯利康制药公司一款预防新冠药物上市,称其可被用于免疫系统有缺陷或对新冠疫苗有严重反应的人群。欧洲药管局当天发表声明说,该机构人用药品委员会推荐批准注射药物Evusheld上市。这款药物由阿斯利康公司研发,用于预防12岁及以上人群感染新冠病毒。

  • 【欧洲药管局推荐批准阿斯利康预防新冠药物上市】欧洲药品管理局24日推荐批准英国阿斯利康制药公司一款预防新冠药物上市,称其可被用于免疫系统有缺陷或对新冠疫苗有严重反应的人群。欧洲药管局当天发表声明说,该机构人用药品委员会推荐批准注射药物Evusheld上市。这款药物由阿斯利康公司研发,用于预防12岁及以上人群感染新冠病毒。

  • 市场消息:欧洲药品管理局(EMA)可能会在几周内就阿斯利康新冠注射剂Evusheld做出决定。

  • 【英国批准阿斯利康的Evusheld用于不宜接种疫苗的成年人】根据一份声明,英国药品和医疗产品监管机构已批准阿斯利康的Evusheld用于不太可能产生新冠疫苗免疫应答或不宜接种疫苗的成年人。称一项成人临床试验发现,Evusheld可将出现新冠症状的风险降低77%,单剂保护力至少可持续6个月。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐